Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

This post-market surveillance study monitors real-world use of lorlatinib (brand name Lorviqua) in adult patients with a specific type of advanced lung cancer in South Korea. The study collects safety and effectiveness data as the drug is used in routine clinical practice. **You may be eligible if...** - You are an adult being treated with lorlatinib for ALK-positive metastatic non-small cell lung cancer (NSCLC) - You have provided written informed consent **You may NOT be eligible if...** - You are not being treated with lorlatinib as part of your standard care - You do not have the ALK gene mutation in your lung cancer - You are under 18 years old Talk to your doctor to see if this trial is right for you.